REZENOPY Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rezenopy, and when can generic versions of Rezenopy launch?
Rezenopy is a drug marketed by Summit Biosci and is included in one NDA.
The generic ingredient in REZENOPY is naloxone hydrochloride. There are twelve drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rezenopy
A generic version of REZENOPY was approved as naloxone hydrochloride by HOSPIRA on September 24th, 1986.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for REZENOPY?
- What are the global sales for REZENOPY?
- What is Average Wholesale Price for REZENOPY?
Summary for REZENOPY
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Patent Applications: | 1,704 |
DailyMed Link: | REZENOPY at DailyMed |
![REZENOPY drug patent expirations Drug patent expirations by year for REZENOPY](/p/graph/s/t/REZENOPY-patent-expirations.png)
US Patents and Regulatory Information for REZENOPY
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Summit Biosci | REZENOPY | naloxone hydrochloride | SPRAY;NASAL | 215487-001 | Apr 19, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |